These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27934817)

  • 1. Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections.
    Saiprasad PV; Krishnaprasad K
    Indian J Med Microbiol; 2016; 34(4):416-420. PubMed ID: 27934817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment.
    Folgori L; Bielicki J; Heath PT; Sharland M
    Curr Opin Infect Dis; 2017 Jun; 30(3):281-288. PubMed ID: 28306563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
    Ruiz Ramos J; Salavert Lletí M
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):45-54. PubMed ID: 31131592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Bassetti M; Righi E; Dimopoulos G
    Future Microbiol; 2014; 9(9):1053-69. PubMed ID: 25340835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study.
    Davido B; Bouchand F; Dinh A; Perronne C; Villart M; Senard O; Salomon J
    Int J Antimicrob Agents; 2017 Aug; 50(2):142-147. PubMed ID: 28694232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.
    Karageorgopoulos DE; Wang R; Yu XH; Falagas ME
    J Antimicrob Chemother; 2012 Feb; 67(2):255-68. PubMed ID: 22096042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.
    Martirosov DM; Lodise TP
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):266-75. PubMed ID: 27033631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin.
    Giske CG
    Clin Microbiol Infect; 2015 Oct; 21(10):899-905. PubMed ID: 26027916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.